Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of September 2023. The filing, dated September 4, 2023, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document acts as a conduit for the attached press release rather than a standalone financial statement.
Material Changes
No material financial changes versus prior periods are detailed within the text of this Form 6-K. The filing indicates that material information is contained in the referenced press release, the content of which is not included in the provided source text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These elements are presumed to be located in the attached Exhibit 99.1 press release, which is not provided in the input.
Key Facts for Investor Verification
- Verify the content of the press release dated September 4, 2023 (Exhibit 99.1), as this filing incorporates it by reference.
- Confirm the specific announcement made by the company on September 4, 2023, as the Form 6-K itself contains no operational or financial details.
- Note that the filing is signed by Tim Dyer, Chief Executive Officer.